Top 50 Ai For Computational Biology in Asia

Artivila Therapeutics utilizes an AI-powered drug discovery engine that integrates computational chemistry and synthetic biology to identify new drug targets in oncology, autoimmune diseases, and neurodegenerative disorders. The platform significantly reduces research and development costs and timelines while increasing the probability of successful drug outcomes for unmet medical needs.

Tianhu Technology specializes in computational chemistry and AI-driven protein design, focusing on enzyme modification and drug molecule development to enhance drug efficacy and reduce manufacturing costs. By leveraging extensive protein sequence data, the company delivers tailored solutions that improve product performance and shorten R&D cycles across various biopharmaceutical applications.

DenovAI Biotech utilizes artificial intelligence and computational molecular biophysics to design proteins tailored for specific applications in biotechnology. This approach addresses the challenge of time-consuming and costly protein development by streamlining the design process, enabling faster and more efficient production of functional proteins.

CytoReason develops a cell-centered computational model that analyzes biological data to map disease mechanisms and treatment effects. This technology enables pharmaceutical companies to prioritize drug development and make data-driven decisions by providing insights into drug performance across diverse patient populations.

Tushen Zhihe provides artificial intelligence-driven protein design services that utilize computational modeling and machine learning algorithms to optimize protein structures for specific functions. This technology addresses the challenges of traditional protein engineering by accelerating the design process and improving the accuracy of protein functionality predictions.

TandemAI provides a physics-based and AI-driven platform that integrates computational analyses with wet lab experimentation to enhance drug discovery workflows. By offering a collaborative workspace and advanced algorithms, TandemAI enables research teams to accelerate the development of new therapeutics more efficiently than traditional methods.

Scala Biodesign utilizes a one-shot computational platform that combines evolutionary analysis and AI to enhance the stability, yield, and specificity of proteins for therapeutic and industrial applications. This technology addresses the limitations of natural proteins, which often lack the required resilience and efficiency for modern medical and manufacturing needs.

GENOBOTICS AI provides a cloud‑native platform that applies deep‑learning models to automatically annotate genomic variants and predict their therapeutic relevance. Users upload standard formats (VCF, BAM, FASTQ) and receive batch‑processed results within minutes via RESTful APIs or an interactive dashboard, with end‑to‑end encryption and HIPAA/GDPR compliance for pharmaceutical, biotech, and academic precision‑medicine teams.

Perpetual Medicines develops a computational peptide drug discovery engine that utilizes advanced computational physics and AI technologies to explore untapped peptide chemical space. The platform targets previously undruggable biological targets, enhancing the efficiency and quality of peptide drug candidates.

Algorithmic Biologics develops a software platform that enhances molecular testing workflows through advanced computational applications, including compression algorithms for next-generation sequencing. This technology significantly reduces library preparation costs by over 60%, making molecular diagnostics more accessible and efficient for healthcare providers.

Zhiyao Technology utilizes artificial intelligence and machine learning techniques, including molecular modeling and deep learning, to enhance the efficiency and success rate of drug discovery for small molecules and proteins. The company provides software and technical services to pharmaceutical firms and research institutions, addressing the challenges of high costs and low success rates in new drug development.

Huili Bio is a synthetic biology platform that utilizes computational design to engineer enzymes for specific biochemical applications. The platform aims to enhance the efficiency of bioprocesses in industries such as pharmaceuticals and agriculture by providing tailored enzyme solutions.

Medvolt is an AI platform that utilizes generative AI and physics-based simulations to enhance early-stage drug discovery and repurposing, significantly reducing pre-clinical discovery time by threefold and costs by fifteenfold. The platform's modular design allows pharmaceutical and biotech companies to efficiently generate novel compounds and therapeutic targets while minimizing the risk of failure in drug development.

The startup utilizes artificial intelligence and big data analytics to enhance drug discovery and development for cancers and rare diseases. Their in-house research facility focuses on accelerating the identification of effective treatments, addressing the lengthy and costly process of bringing new drugs to market.

ZipBio uses generative AI to design compact, multispecific protein therapeutics called Zip® drugs, enabling the creation of novel biologics that are difficult to produce with traditional methods. These smart proteins target unmet medical needs across various disease areas, and the company monetizes its pipeline through licensing, partnerships, and eventual product sales. The platform aims to accelerate drug development by compressing biological complexity into engineered therapeutic candidates.

3BIGS utilizes bio big data and AI-driven platforms to analyze next-generation sequencing (NGS) data, identifying patterns, mutations, and biomarkers for drug discovery and healthcare insights. The company addresses the challenge of extracting actionable information from vast biological datasets, accelerating the development of targeted therapies and improving patient outcomes.

Engine Biosciences uses machine learning and high‑throughput biology to map genetic interactions in complex disease networks, identifying therapeutic targets and biomarkers for defined patient groups. It translates these insights into precision medicines and companion diagnostics, focusing on solid tumor indications. The company also offers its platform and assets for partnership to accelerate R&D and clinical development.

Datomics Group provides a bioinformatics platform that utilizes machine learning and AI to analyze large volumes of scientific data, enhancing research efficiency and decision-making in life sciences. The platform integrates with laboratory instruments and complies with regulatory standards, enabling faster product development and optimized operations.

CarbonSilicon AI provides an AI-driven platform for drug discovery that integrates deep learning, knowledge graphs, and 3D modeling to enhance target identification and safety predictions. This technology streamlines the drug development process, reducing time and costs associated with traditional research methods.

Pasbox utilizes artificial intelligence to analyze molecular biology data, providing healthcare solutions that enhance patient outcomes. The platform addresses inefficiencies in data interpretation and decision-making in clinical settings, enabling faster and more accurate diagnostics.

This company analyzes microbiome data using AI to provide insights into human health. Their platform helps researchers and healthcare professionals understand the role of the microbiome in disease and develop personalized interventions.

Protai utilizes machine learning and mass spectrometry-derived proteomics data to create a vertically integrated platform for drug discovery. This technology enables precise targeting of complex disease drivers, facilitating the identification of novel therapeutic targets and improving the development of effective treatments.

The startup develops targeted cancer therapeutics through advanced computational biology and drug discovery technologies, enabling precise identification of potential drug candidates. This approach addresses the challenge of inefficient cancer treatment development, facilitating faster and more effective therapies for clinicians and patients.

Villanelle Life develops AI-driven platforms for drug discovery, early disease screening, and diagnostic support. Their technology aims to accelerate the identification of potential drug candidates and improve disease detection and diagnosis.

Xilingyuan Pharmaceutical utilizes advanced computational modeling and data analytics to streamline the drug development process, significantly reducing time-to-market for new therapeutics. The company addresses the inefficiencies and high costs associated with traditional drug discovery methods, enabling faster and more cost-effective solutions for pharmaceutical innovation.

Enzymit develops a cell-free bioproduction platform utilizing computational protein design and high-throughput testing to create novel enzymes for various industries, including biochemicals and health. This technology addresses the inefficiencies and high costs associated with traditional enzymatic manufacturing processes, enabling faster and more sustainable production.

Zion Pharma is a drug discovery platform that utilizes computational biology and machine learning to identify potential drug candidates more efficiently. The platform addresses the high costs and lengthy timelines associated with traditional drug development processes by streamlining target identification and lead optimization.

Cimplrx utilizes its Explainable Artificial Intelligence platform, CEEK-CURE, to streamline drug discovery by generating predictive models for compound design and target identification. This technology addresses the inefficiencies in traditional drug development processes by automating data analysis and visualization, enabling faster and more informed decision-making in the identification of new drug candidates.

Yanyin Technology offers an AI-driven digital collaboration platform for biomedical research, integrating tools for molecular biology, electronic lab records, and data management. This platform enhances research efficiency by streamlining experimental processes and improving data traceability, addressing the challenges of fragmented workflows in scientific research.

MolNavi utilizes molecular navigation technologies to enhance drug discovery and materials science processes. The company focuses on improving the efficiency and accuracy of identifying viable compounds, addressing the lengthy and costly nature of traditional drug development.

PromiseBio provides a cloud-based AI platform for broad-range epiproteomic analyses using standard mass-spectrometry data. This platform uncovers hidden insights into Post Translational Modifications (PTMs) that regulate protein activity, crucial for understanding autoimmune diseases. The resulting explainable, biologically-relevant data supports precision medicine applications like treatment selection and biomarker discovery.

Liying Bio develops protein products through advanced platforms such as AI-assisted protein design and high-throughput structural biology, enabling precise modifications to protein structures. The company addresses the need for high-performance proteins in medical nutrition, cosmetics, and diagnostics by providing tailored solutions that enhance protein stability and functionality.

Standigm utilizes artificial intelligence to enhance drug discovery through first-in-class target identification and lead optimization, significantly reducing the average material optimization time from 4.5 years to 1.5 years. The platform provides end-to-end solutions that improve the efficiency and success rates of new drug development processes.

Microlysis utilizes artificial intelligence and machine learning to analyze thousands of videos of cell-cell interactions, enhancing the development of targeted cell therapies. This approach aims to improve the efficacy and precision of treatments for various medical conditions.

BJ Biopharma utilizes proprietary AI algorithms to design and test drug candidates, streamlining the drug development process from molecule design to in vitro and in vivo testing. This approach addresses the inefficiencies in traditional drug discovery, significantly accelerating the time to market for new therapeutics.

Mojia Bioscience employs bio-manufacturing techniques to create sustainable materials that significantly reduce carbon emissions in industrial processes. The company provides carbon-neutral alternatives to traditional manufacturing, contributing to sustainable development and minimizing environmental impact.

1Cell provides an AI-powered single‑cell liquid biopsy platform that isolates circulating tumor cells and generates multi‑omics profiles in real time. The system combines high‑throughput cell capture hardware with machine‑learning analytics to deliver molecular signatures for early cancer detection, therapy response prediction, and disease monitoring.

Eleven Therapeutics utilizes synthetic chemistry and AI algorithms to develop RNA therapeutics that optimize safety, efficiency, and duration of effect. Their platform maps the vast chemical space of RNA molecules, addressing the need for precise and effective therapeutic solutions in the rapidly evolving field of RNA-based medicine.

Scitech Pharma utilizes its proprietary SigmaHIT® program to design and develop small molecule drugs targeting oncology, autoimmune diseases, and central nervous system disorders. The company accelerates drug development by rapidly synthesizing and optimizing candidates through AI-driven methodologies, enhancing the efficiency of bringing new therapies to market.

Adagene operates an AI‑driven antibody discovery platform that models the full conformational landscape of target proteins to identify high‑affinity binders. The system generates three proprietary formats—NEObody for targeting previously inaccessible epitopes, SAFEbody for tumor‑localized activation via precision masking, and POWERbody that combines masking with bispecific, ADC, or T‑cell engager configurations. The company offers these candidates as licensed assets or co‑development projects to biopharma partners seeking safer, multi‑modal oncology therapeutics.

BluMaiden uses advanced AI-guided discovery and computational chemistry to uncover human-derived natural product small molecules hidden within human biology. This approach translates "chemical dark matter" into novel therapeutic drug candidates that are inherently aligned with human biology for enhanced safety and specificity. The company integrates metagenomics, chemistry, and human physiology to accelerate the translation of overlooked molecular relationships into new medicines.

SK Therapeutics is an AI-driven platform that accelerates drug development by utilizing machine learning algorithms to identify potential drug candidates and optimize their efficacy. This approach addresses the lengthy and costly traditional drug discovery process, significantly reducing time-to-market for new therapeutics.

DP Technology develops the "Deep Insight Universe" AI model system to enhance scientific research and industrial R&D by transitioning methodologies from experimental trial-and-error to pre-trained models. This approach addresses inefficiencies in research processes across disciplines such as biomedicine, energy, materials, and information science, enabling faster and more accurate outcomes.

Zilixir Biotech offers an AI-powered platform for predicting and designing protein structures. Their technology enables researchers to accelerate protein engineering and development for various applications.

BigHat Biosciences utilizes a machine learning-guided antibody design platform, Milliner, which integrates synthetic biology and high-speed wet lab processes to rapidly synthesize and characterize recombinant antibodies. The company focuses on developing safer and more effective antibody therapies for patients with challenging diseases, enhancing treatment options in the biopharmaceutical landscape.

Farcast Biosciences develops the Farcast Human Tumor Microdynamics Platform, which generates multimodal data to model tumor response and resistance to therapies using true-to-human biological systems. This technology enables researchers to identify effective treatment regimens and predict patient responses with greater accuracy, addressing the challenge of personalized cancer therapy.

The startup operates a gene therapy platform that utilizes artificial intelligence and big data for promoter and capsid engineering, along with mechanical modeling, to develop efficient and cost-effective treatments. It focuses on providing targeted gene therapies for rare and incurable diseases, enhancing the healthcare sector's ability to deliver optimal therapeutic solutions.

Deyun Kangrui specializes in the research and development of full-chain single-cell multi-omics technology, enabling comprehensive analysis of cellular functions and interactions. This technology addresses the need for precise biological insights in drug development and personalized medicine, enhancing the understanding of complex diseases at the single-cell level.

QuantHealth utilizes a proprietary AI platform to conduct patient-centric drug simulations, enabling pharmaceutical and biotech companies to run extensive variations of clinical trials. This approach addresses the high failure rate of drugs in development, significantly increasing the probability of trial success and facilitating the discovery of new clinical opportunities.

CyberomiX utilizes digital technology to analyze DNA and gene expression at the cellular level, focusing on various diseases and conditions. The company provides a streamlined workflow for drug discovery and diagnostics by decoding genomic information from diverse clinical samples.